Bevacizumab in the treatment of metastatic colorectal cancer

By Caprioni Francesco   Fornarini Giuseppe  

Future Oncology, Vol. 3, Iss. 2, 2007-04 ,pp. : 141-148

Future Medicine

Access to resources Recommend Favorite

A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients

By Ogawa Kohei   Ueno Takao   Kato Ken   Nishitani Hitoshi   Akiyoshi Kohei   Iwasa Satoru   Nakajima Takako   Hamaguchi Tetsuya   Yamada Yasuhide   Hosokawa Ayumu   Sugiyama Toshiro   Shimada Yasuhiro  

International Journal of Clinical Oncology, Vol. 18, Iss. 6, 2013-12 ,pp. : 1020-1024

Springer Publishing Company

Access to resources Recommend Favorite

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

By Rosati Gerardo   Avallone Antonio   Aprile Giuseppe   Butera Alfredo   Reggiardo Giorgio   Bilancia Domenico  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 257-264

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1505-1513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer

By Saif Muhammad   Elfiky Aymen   Salem Ronald  

Annals of Surgical Oncology, Vol. 14, Iss. 6, 2007-06 ,pp. : 1860-1869

Springer Publishing Company

Access to resources Recommend Favorite